C5a receptor (CD88) blockade protects against MPO-ANCA GN

265Citations
Citations of this article
173Readers
Mendeley users who have this article in their library.

Abstract

Necrotizing and crescentic GN (NCGN) with a paucity of glomerular immunoglobulin deposits is associatedwith ANCA. Themost common ANCA target antigens are myeloperoxidase (MPO) and proteinase 3. In a manner that requires activation of the alternative complement pathway, passive transfer of antibodies to mouse MPO (anti-MPO) induces a mouse model of ANCA NCGN that closely mimics human disease. Here, we confirm the importance of C5aR/CD88 in the mediation of anti-MPO-induced NCGN and report that C6 is not required. We further demonstrate that deficiency of C5a-like receptor (C5L2) has the reverse effect of C5aR/CD88 deficiency and results in more severe disease, indicating that C5aR/CD88 engagement enhances inflammation and C5L2 engagement suppresses inflammation. Oral administration of CCX168, a small molecule antagonist of human C5aR/CD88, ameliorated anti-MPO-induced NCGN in mice expressing human C5aR/CD88. These observations suggest that blockade of C5aR/CD88 might have therapeutic benefit in patients with ANCA-associated vasculitis and GN. © 2014 by the American Society of Nephrology.

Cite

CITATION STYLE

APA

Xiao, H., Dairaghi, D. J., Powers, J. P., Ertl, L. S., Baumgart, T., Wang, Y., … Jennette, J. C. (2014). C5a receptor (CD88) blockade protects against MPO-ANCA GN. Journal of the American Society of Nephrology, 25(2), 225–231. https://doi.org/10.1681/ASN.2013020143

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free